Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBT (2016 - 2025)

Historic EBT for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $21.5 million.

  • Amphastar Pharmaceuticals' EBT fell 5488.33% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.1 million, marking a year-over-year decrease of 2863.99%. This contributed to the annual value of $195.2 million for FY2024, which is 728.66% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' EBT stood at $21.5 million, which was down 5488.33% from $39.3 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year EBT high stood at $63.6 million for Q3 2023, and its period low was $5.1 million during Q1 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' EBT averaged around $35.8 million, with its median value being $33.6 million (2023).
  • Per our database at Business Quant, Amphastar Pharmaceuticals' EBT soared by 104527.93% in 2021 and then plummeted by 5488.33% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' EBT (Quarter) stood at $27.2 million in 2021, then surged by 93.0% to $52.4 million in 2022, then dropped by 0.98% to $51.9 million in 2023, then fell by 4.88% to $49.4 million in 2024, then tumbled by 56.43% to $21.5 million in 2025.
  • Its EBT stands at $21.5 million for Q3 2025, versus $39.3 million for Q2 2025 and $30.9 million for Q1 2025.